EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany

An Observational Study

verfasst von

Wolfgang Schuette, Peter Schirmacher, Wilfried Ernst Erich Eberhardt, Juergen R. Fischer, J. Matthias Graf Von Der Schulenburg, Joerg Mezger, Christian Schumann, Monika Serke, Silke Zaun, Manfred Dietel, Michael Thomas

Abstract

Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non-small cell lung cancer (NSCLC). We investigated the clinicopathologic characteristics associated with EGFR mutations and their impact on realworld treatment decisions and outcomes in Caucasian patients with advanced NSCLC. Methods: REASON (NCT00997230) was a noninterventional multicenter study in patients (≥18 years) with stage IIIb/IV NSCLC, who were candidates for EGFR mutation testing and first-line systemic treatment, but not eligible for surgery or radiotherapy. Patients were followed up according to normal clinical practice and assessed for primary (correlation of mutation status with baseline characteristics) and secondary endpoints (first-line treatment decision). Results: Baseline data were obtained for 4,200 patients; 4,196 fulfilled the inclusion criteria; EGFR mutations were detected in 431 patients; no EGFR mutations were detected in 3,590 patients; mutation status was not evaluable in 175 patients. In multivariate analysis, the odds of EGFR mutations were significantly higher (P < 0.0001) in females versus males (odds ratio: 1.85; 95% confidence interval, 1.48-2.32), never-smokers versus smokers (3.64; 2.91-4.56), and patients with adenocarcinoma versus other histologic subtypes (2.94; 2.17-4.08). The most commonly prescribed first-line systemic treatments were: EGFR-TKIs in EGFR mutation-positive NSCLC (56.6%) and combination chemotherapy in EGFR mutation-negative NSCLC (78.5%). Conclusions: This represents the largest dataset for EGFR mutations in Caucasian patients and shows EGFR mutations to be most prevalent in females with adenocarcinoma who had never smoked. Impact: These findings add to our understanding of the prognostic and predictive factors of NSCLC, supporting future improved treatment selection.

Organisationseinheit(en)

Center for Health Economics Research Hannover (CHERH)

Externe Organisation(en)

Krankenhaus Martha-Maria Halle-Dölau
Ruprecht-Karls-Universität Heidelberg
Universität Duisburg-Essen
Klinik Löwenstein gGmbH
Universität Ulm
AstraZeneca
Charité - Universitätsmedizin Berlin
Translational Lung Research Center Heidelberg (TLRC)
St. Vincentius-Kliniken Karlsruhe
Lungenklinik Hemer

Typ

Artikel

Journal

Cancer Epidemiology Biomarkers and Prevention

Band

24

Seiten

1254-1261

Anzahl der Seiten

8

ISSN

1055-9965

Publikationsdatum

08.2015

Publikationsstatus

Veröffentlicht

Peer-reviewed

Ja

ASJC Scopus Sachgebiete

Epidemiologie, Onkologie

Ziele für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Elektronische Version(en)

https://doi.org/10.1158/1055-9965.EPI-14-1149 (Zugang: Offen)